POSTN (Periostin), as an emerging biomarker, shows potential to complement existing CAD biomarkers such as high-sensitivity C-reactive protein (hs-CRP) and cardiac troponin I (cTnI), thereby contributing to the establishment of a multidimensional biomarker evaluation system encompassing “structure—inflammation—damage”. This evidence concerns the gene POSTN and coronary artery disorder.